Anika Therapeutics stock forecast
Anika Therapeutics (AKP) Stock Forecast & Price Target
AKP Analyst Ratings
AKP Stock 12 Month Forecast
Average Price Target
CHF18.89▲(0.00% Upside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Michael Petusky | Barrington | CHF18.89 | buy | ― | Reiterated | 11/09/26 | ||
| Madison Elsaadi | B. Riley Securities | CHF17.24→CHF18.89 | buy | ― | Initiated | 09/18/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Michael PetuskyBarrington | BuyReiteratedCHF18.89 | 11/09/26 | ― | ||
| Madison ElsaadiB. Riley Securities | BuyInitiatedCHF17.24→CHF18.89 | 09/18/26 | ― |
Best Analysts Covering Anika Therapeutics
Copying Michael Petusky's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +0.84% per trade.
Copying Michael Petusky's trades and holding each position for 1 Year would result in 32.14% of your transactions generating a profit, with an average return of -6.72% per trade.
Copying Michael Petusky's trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -13.77% per trade.
AKP Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 |
| Buy | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 2 | 2 | 3 | 3 | 4 |
In the current month, AKP has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AKP average Analyst price target in the past 3 months is 18.89.
AKP Financial Forecast
AKP Earnings Forecast
Next quarter’s earnings estimate for AKP is CHF 0.11 with a range of CHF 0.11 to CHF 0.11. The previous quarter’s EPS was CHF 0.24. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
AKP Sales Forecast
Next quarter’s sales forecast for AKP is CHF 24.83M with a range of CHF 24.77M to CHF 24.89M. The previous quarter’s sales results were CHF 25.56M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
